Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment

Twenty-six patients with advanced prostatic carcinoma refractory to conventional endocrine treatment were treated with a new oral nonsteriodal antiandrogen, flutamide. There were 6 responders and 20 failures. No serious toxicity attributable to flutamide was observed.